The Safe Drinking Water Act Amendments of 1986 required that the U.S. Environmental Protection Agency (EPA) establish standards for 83 contaminants by June 1989, and at least 25 added standards by January 1991, then 25 more every three years hence. Conceptually, the regulatory process employed by EPA consists of two steps. First, a detailed health risk assessment of a contaminant is performed in order to determine the Maximum Contaminant Level Goal (nonenforceable health goal) in water that should result in no known or anticipated health effects and allows adequate margin of safety. Second, the results of risk assessment and management (taking best available technology, treatment techniques, cost, and other means into consideration) are combined to derive the Maximum Contaminant Level (enforceable standard) which is set as close to the MCLG as feasible. With this overall regulatory process in mind, a detailed risk assessment process (hazard identification, dose-response assessment, human exposure assessment, and risk characterization) used in setting drinking water standards is discussed. In addition, this article discusses our efforts in exploring new and improved risk assessment methodologies addressing the mechanism of action of toxicants, relative source contribution, weight of evidence, carcinogenic potency, and toxicokinetics.
INTRODUCTION
HE SAFE DRINKING WATER ACT (SDWA), as amended in 1986, requires the U.S. Environmental Protection T Agency (EPA) to publish "maximum contaminant level goals" (MCLGs) for contaminants which, in the judgment of the Administrator, "may have an adverse effect on the health of persons and which are known or anticipated to occur in public water systems." MCLGs are to be set at a level at which "no known or anticipated adverse effects on the health of persons occur and which allows an adequate margin of safety." At the same time EPA publishes a MCLG, which is a nonenforceable health goal, it must also promulgate a National Primary Drinking Water Regulation (NPDWR) which includes either (1) a maximum contaminant level (MCL), or (2) a required treatment technique. A treatment technique may be set only if it is not "economically or technologically feasible" to ascertain the level of a contaminant. A MCL must be set as close to the MCLG as feasible. Under the Act, "feasible" means "feasible with the use of the best technology, treatment techniques and other means which the Administrator finds are available, after examination for efficacy under field conditions and not solely under laboratory conditions (taking cost into consideration)." Under the 1986 Amendments to the SDWA, EPA was to complete the promulgation of NPDWRs for 83 contaminants, in three phases, by June 19, 1989 . After 1989 , an additional 25 contaminants must be regulated every three years. This article focuses on risk assessment (i.e., hazard identification, dose-response assessment, human exposure assessment, and risk characterization) approaches, providing the basis for MCLGs for noncarcinogens and carcinogens. 
Risk assessment basis for MCLGs
Quantification of noncarcinogenic effects. The reference dose (RfD) is an estimate, with an uncertainty factor spanning perhaps an order of magnitude. of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious health effects during a lifetime. The R D is derived from a no-or lowest-observed-adverse-effect level (NOAEL or LOAEL, respectively) that has been identified from a subchronic or chronic human or animal data. The NOAEL or LOAEL is then divided by the uncertainty factor to derive the RfD. EPA has established certain guidelines (shown below) to determine which uncertainty factor should be used during a particular extrapolation:
10-Average human to sensitive human l0-Animal to human s ICLLOAEL to NOAEL s I@-Short-term to long-term exposure < 10-Minimum to complete database Additional "best scientific judgment" considerations may necessitate the use of an additional uncertainty factor of 1 to 10. These other considerations include the significance of the adverse health effect, pharmacokinetic factors, and the counterbalancing of beneficial effects for essential nutrients.
From the RfD, a drinking water equivalent level (DWEL) is calculated by multiplying the RtD by an assumed adult body weight of 70 kg and then dividing by an average daily wafer consumption of 2 L per day. The DWEL assumes the total daily exposure to a substance is from drinking water. The MCLG is determined by multiplying the DWEL by the percentage of the total daily exposure contributed by drinking water, called the relative source contribution. Generally, EPA assumes that the relative source contribution from drinking water is 20% of the total exposure, unless other chemical-specific exposure data are available. The Agency is in the midst of developing human exposure models to include dermal absorption and volatilization in the determination of body burden and relative source contribution from all drinking water sources.
Quantification of carcinogenic effects. A separate health assessment system is used for potentially "nonthreshold' chemicals with carcinogenic potential. Carcinogenicity is assumed generally to be a nonthreshold phenomenon, meaning that any exposure is assumed to represent some finite level of risk in the absence of sufficient negative information. Precedence was given to this method in the House Report that accompanied the SDWA indicating that MCLGs for nonthreshold toxicants (i.e., carcinogens) should be set at zero. A summary of EPA's carcinogen classification scheme is as follows:
Group A: Human carcinogen (sufficient evidence from epidemiological studies) If toxicological evidence leads to the classification of the contaminant as a human or probable human carcinogen, the MCLG is set at zero. Mathematical models are used to calculate drinking water concentrations associated with estimated excess cancer risk levels (e.g., for example.
indicates a possibility of one additional case of cancer for every 10,000 people exposed over a 70-year lifetime; a risk of to-' indicates one additional cancer per 100,000 exposed individuals. The data used in these risk estimates usually come from lifetime exposure studies in animals. To predict the risk for humans, these animal doses must be converted to equivalent human doses. This conversion includes correction for noncontinuous animal exposure, less than lifetime studies, and differences in animal/human surface area and weight. The size differential is assumed t o be proportional to the difference in body surface area, which is approximated by the cube root of the ratio of the animal and human body weights. It is assumed that the average adult human body weight is 70 kg.
For contaminants with carcinogenic potential, drinking water concentrations are correlated with the carcinogenic risk estimates by employing a cancer potency value together with the assumption for lifetime exposure via ingestion of 2 L of water per day. The cancer unit risk is usually derived from a linearized multistage model with a 95% upper confidence limit providing a low-dose estimate. The true cancer risk to humans is not likely to exceed this upper limit estimate and, in fact, may be zero.
Excess cancer risk estimates may also be calculated using other models such as the one-hit, Weibull, logit, and probit models. Given the current limited understanding of the biological mechanisms involved in carcinogenesis, no one of these models can be said to predict risk more accurately than another. Each model is based on differing assumptions; thus. the estimates derived for the various models can differ by several orders of magnitude.
A number of uncertainties are associated with the scientific database used to calculate and support cancer risk estimates. For example, usually cancer studies are performed with experimental animals, and extrapolating these data to humans is difficult due to a lack of understanding of the biological mechanisms involved. Insufficient knowledge concerning the health effects of contaminants in drinking water; the impact of the experimental animal's age, gender, and species; and the nature of the target orgadsystem examined adds uncertainty to the use of the database. Dose-response data are gathered in animals at high levels of exposure rather than at the lower levels simulating human exposure. Finally, most exposures are to more than one contaminant, and little is known regarding possible synergistic or antagonistic effects associated with complex mixtures. The Agency concluded that all of these uncertainties support use of the generally more conservative linearized multistage model for estimating cancer risk rates. Using one model also fosters a consistency of approach. However, some data suggest that other models may be more appropriate than the linearized multistage model. The cancer guidelines help in determining risk, but evaluating carcinogenic potential is controversial in light of the divergent interpretations of the scientific community.
Derivation oJ'MCLGs. Each chemical is evaluated for evidence of carcinogenicity via ingestion. In most cases. the Agency places Group A, B,, and B, contaminants into Category I (strong evidence of carcinogenicity), Group C into Category 11 (limited evidence of carcinogenicity), and Group D and E into Category I11 (inadequate or no evidence of carcinogenicity). However, when there is additional information on cancer risks from drinking water ingestion (taking into account weight of evidence of carcinogenicity, mechanism of toxicity, cancer potency, pharmacokinetics, and exposure) additional scrutiny may result in placing the contaminant into a different category. Tissue dosimetry and response following ingestion of a chemical should be carefully assessed since a biologically effective dose is required to induce toxicity. Again, the consideration of applied and delivered doses is an integral part of risk assessment. Thus, any route-to-route extrapolation should be undertaken with extreme caution.
Asbestos and cadmium are examples where the categorization was adjusted based on the evidence of carcinogenicity via ingestion. Specifically, asbestos has been shown to be a human carcinogen through inhalation exposure and is classified by EPA as Group A (human carcinogen). However, the Agency believed that the limitations of the available dose-response data from dietary ingestion of asbestos justifies treating this contaminant as a Category 11 instead of Category I. Similarly, EPA classified cadmium in Group B, (probable human carcinogen) based upon animal and human evidence of lung cancer from inhalation exposure. Chronic oral animal studies with cadmium have shown kidney damage but no carcinogenic activity and ingestion-specific human data lo-', lo-"). A lifetime risk of are not available. Therefore, in setting an MCLG for cadmium in drinking water, EPA concluded that the lack of cancer dose-response evidence from ingestion of cadmium justifies considering this pollutant as a Category I11 instead of Category I. In the case of styrene, where the Agency's cancer classification is unresolved, EPA applied its categorization approach to derive an MCLG. The Agency considered carefully the overall weight of evidence for carcinogenicity, especially: ( I ) the comparatively low estimated cancer potency and (2) the lack of carcinogenic response in an adequately conducted drinking water study. In addition, styrene is not likely to be widespread in drinking water. Consequently, EPA placed styrene in Category I1 instead of Category I.
The Agency's existing policy is to set MCLGs for Category I chemicals at zero since it is assumed that there is no threshold for carcinogens. The MCLG for Category I1 contaminants is calculated either by (1) using noncarcinogenic endpoints (RfD/DWEL approach) with an additional uncertainty factor ranging from I to 10 to take into account the carcinogenic potential of the contaminant or (2) deriving the theoretical excess lifetime cancer risk in the range of using a conservative (i.e., linearized multistage) mathematical model. The first approach generally is used; however, the second is considered when valid noncarcinogenic data are absent and adequate experimental data are available to quantify the cancer risk. The MCLGs for Category I11 contaminants are generated by using the RfDIDWEL approach.
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CONCLUSIONS
The Agency has been interested in reviewing its MCLG development process as new and/or improved risk assessment methodologies become available. Briefly these include:
Use of mechanisms of action data in cancer classification scheme Application of maximum tolerated dose (MTD) and its implication in risk assessment Risk assessment of complex mixtures using toxicity equivalency factor (TEF) approach Role of essentiality versus toxicity in risk assessment of trace elements Application of benchmark dose approach in the derivation of reference dose Consideration of mechanism of carcinogenicity in the selection of risk assessment model (i.e., two-stage, receptor-mediated, etc.) Incorporation of data on active metabolites in assessing cancer risk Estimation of human exposure parameters using physiologically based tissue dosimetry and response models Development and validation of human exposure models designed to generate realistic predictions of exposure to chemicals Thus, the primary focus on periodic review of the state-of-the-art of risk assessment methodologies must be able to provide scientifically sound background to support policy making and regulatory decisions.
